CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR 时代的因材制宜：推进 CAR-T 与 CAR NK 细胞治疗
英文原题：Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies.
查看英文原题
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
异体CAR NK细胞的过继转移作为一种抗癌手段具有巨大前景，因为NK细胞的制造和基因修饰相对容易，从而带来可负担的定价。与CAR-T 细胞疗法在治疗B细胞恶性肿瘤中显著的疗效相比，CAR NK细胞抗肿瘤特性的严格临床和临床前评估一直滞后。在这篇简要综述中，我们总结了NK细胞的生物学特征，这些特征可能有助于界定CAR NK细胞的治疗生态位，并创建更有效的基于NK细胞的抗癌产品。此外，我们利用单细胞转录组分析的数据，比较了T细胞和NK细胞作为CAR载体的差异。
展开英文摘要原文
The adoptive transfer of allogeneic CAR NK cells holds great promise as an anticancer modality due to the relative ease of manufacturing and genetic modification of NK cells, which translates into affordable pricing.
Compared to the pronounced efficacy of CAR T cell therapy in the treatment of B cell malignancies, rigorous clinical and preclinical assessment of the antitumor properties of CAR NK cells has been lagging behind. In this brief review, we summarize the biological features of NK cells that may help define the therapeutic niche of CAR NK cells as well as create more potent NK cell-based anticancer products.
In addition, we compare T cells and NK cells as the carriers of CARs using the data of single-cell transcriptomic analysis.
论文信息
- 作者
- Kulemzin S、Evsyukov I、Belovezhets T、Taranin A、Gorchakov A
- 单位
- Almazov National Medical Research Centre, 197341 Saint Petersburg, Russia.Russia
- 文献类型
- 综述
- 期刊
- Journal of personalized medicine2021 Nov 11
- 原文标识
- PubMed 34834534 · DOI 10.3390/jpm11111182
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →